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Abstract 
Cannabis and its derivatives have been used for both medicinal and recreational 
purposes.  The study of this plant led to the discovery of over 60 cannabinoids, 
found exclusively in cannabis, that contribute to the behavioral effects of cannabis 
use, the most common is delta-9-tetrahydrocannabinol.  Cannabinoid receptors 
function to increase activity in the mesolimbic dopamine reward system.  
Dopamine is a neurotransmitter that plays a major role in addition and its 
regulation plays a crucial role in mental and physical well-being.  There is 
evidence that CB1 receptors are important to the reinforcing effects and the 
development of physical dependence on opiate drugs.  Studies have shown that 
increased levels of dopamine are consistent with addiction while reduced levels 
lead to a decline in recreational use.   
The goal of this research is to design, synthesize and develop potential CB1 
receptors that exhibit a neutral cannabinoid antagonist pharmacological profile.       
 
Keywords: Cannabinoids, Cannabinoid receptors, Dopamine, Benzhydryl 
Azetidines, Diols, Oximes, Amines 
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Introduction 
Cannabis sativa, or marijuana, is an Indian hemp that was given its name and 
classification by Linnaeus in 1753.
1
  For centuries, marijuana and its derivatives 
have been used for both medicinal and recreational purposes.  An entire family of 
drugs, called cannabinoids (Figure 1), is found exclusively in cannabis, and each 
may contribute, directly or indirectly, to the behavioral effects associated with 
cannabis use.
1   
  Cannabis effects include enhanced moods (happiness or laughing), 
sensory alterations, enhanced appetite and greater insight/thinking.
2
  The chemistry 
of cannabis is very complex, over 60 cannabinoids have been identified, the most 
common is the principal psychoactive ingredient Δ-9-tetrahydrocannabinol [Δ9-
THC (1)].
1
  Other common natural cannabinoids or “phytocannabinoids” include 
cannabidiol [CBD (2)] and cannabinol [CBN (3)], which exhibit non-psychoactive 
properties.
 2
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Figure 1. “Phytocannabinoids” or Natural Cannabinoids2 
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The discovery of the cannabinoids led to the identification of the endogenous 
cannabinoid system (ECS), which is involved in many physiological processes, 
including appetite, sensation of pain, mood and memory.
3,4
   This system consists 
of two (G-protein)-coupled membrane receptors (CB1 and CB2), endogenous 
ligands (endocannabinoids), and the enzymes and proteins involved in their 
formation and metabolism.
3
  Modulation of this system may be crucial in 
discovering treatments for diseases, such as, drug addiction, obesity, and 
Alzheimer’s. 
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C6H13
CP55, 490
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O
N
N
O
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WIN 55212-2
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Figure 2. Examples of a Non-Classical Cannabinoid (4) and Aminoindole (5)
4
 
Gaoni and Mechoulam (1964) successfully identified the correct chemical structure 
of THC and this discovery led to the synthesis of structurally similar analogs of 
phytocannabinoids, nonclassical cannabinoids (4) and aminoindoles (5).
 4,5
   
The study of one such analog, CP 55,940, (4) provided evidence of the possible 
existence of a high-affinity and stereo-selective binding site, which allowed the 
3 
 
identification and characterization of a cannabinoid receptor.
6
  Radioligands and 
autoradiography helped map these cannabinoid binding sites in the brain.
6
  In 1990 
and 1993 respectively, this mapping was essential to the identification and cloning 
of two cannabinoid G-protein coupled receptors (GCPRs).
 7,8
  These receptors (CB1 
and CB2), belong to the Class A, rhodospin-like family of GPCRs.  G-protein 
coupled receptors activate varying types of G-proteins on the intracellular side of 
the lipid membrane, thus eliciting biochemical responses through different signal 
transduction mechanisms.
9
  CB1 receptors are found primarily in the central 
nervous system, in areas including those that control movement (cerebellum and 
basal ganglia), cognition (cerebral cortex), memory and attention (hippocampus), 
and pain.
10 
 This receptor is also expressed in peripheral tissue (eye and bladder) 
and is responsible for mediating most of the behavioral effects of Δ9-THC. 10  The 
CB2 receptor is found mostly in peripheral tissue in cells of the immune system, 
including the spleen and tonsils,
 11
 and may play a pivotal role in mediating the 
immunosuppressive effects of cannabinoids.
 10
  A recent report described CB2 
receptors present in small amounts in the CNS, compared to CB1 receptors.
12 
 CB1 
and CB2 receptors can mediate different cannabinoid effects and make it possible 
to develop medications that selectively produce therapeutic effects with minimal 
side effects.
 1   
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There are four classes of ligands that characterize CB1 receptor agonists: the 
classical cannabinoids [ex. Δ9-THC (1)], the non-classical cannabinoids [ex. 
CP55,940 (4)], the aminoindoles [ex. WIN55212-2 (5)], and the endogenous 
cannabinoids [ex. Anandamide (6)].
11
  These ligands have a low nanomolar affinity 
for CB1 receptors and are usually non-selective for CB1 over CB2 receptors.  Of the 
previous ligands, Anandamide (6) has shown a significant difference in binding 
affinities for each receptor type [Ki= 61 nM (CB1) and Ki= 1930 nM (CB2)].
13
  
Anandamide [AEA or N- arachidonyl ethanolamine (6)] was isolated from porcine 
brain and has similar properties to the naturally derived agonist Δ9-THC.  Another 
endogenous ligand is 2-arachidonoylgycerol [2-AG (7)], an important 
phosphoglyceride metabolism intermediate.
 13
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Figure 3. Examples of Endogenous Ligands 
13
   
Endocannabinoids (Figure 3) are thought to act as retrograde messengers in the 
nervous system.  They are released by postsynaptic neurons and cross the synaptic 
cleft to stimulate CB1 receptors on presynaptic termini.
13,14
  The activated CB1 
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receptors couple mainly through the Gi/Go class of G proteins to control the 
potassium and calcium channels and reduce the chance of neurotransmitter 
release.
14,15
  This suppression can result in inhibition or disinhibition of neuronal 
circuits, depending on whether the CB1 receptor is expressed on glutamatergic or 
GABergic neurons.
14
  The glutamatergic neurotransmitter system plays an 
important role in information processing and memory function.  Ligands, AEA (6) 
and 2-AG (7), are produced from the metabolism of membrane phospholipids and 
are released immediately into extracellular space.  Inactivation occurs in two steps: 
cellular reuptake, helped by a transporter protein known as anandamide  membrane 
transporter (AMT) and enzymatic hydrolysis by fatty acid amide hydrolase 
(FAAH) or by a monoacyglycerol lipase, for 2-AG (7).
 13
  AEA and 2-AG can be 
re-synthesized as needed.  The therapeutic nature of these endogenous cannabinoid 
system receptors are of great interest because they represent targets for the 
development of new analgesic and anti-inflammatory drug agents.
 13
  
Cannabinoid receptors and endocannabinoids appear to function as 
neuromodulators of many different neurotransmitters than as neurotransmitters 
themselves.
1
  Cannabinoid receptors function to increase activity in the mesolimbic 
dopamine reward system.  They perform this function by potentiating the effects of 
endogenous opioid peptides, which in turn function as neuromodulators of 
dopamine transmission.
1,15
  Dopamine is a neurotransmitter that controls 
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movement, behavior, learning, motivation and reward.  It plays a major role in 
addiction and its regulation plays a crucial role in mental and physical well-being.
2
   
CB1 receptor agonists can increase intracellular dopamine levels in the brain 
similar to cocaine and there is evidence that the CB1 receptors are important to the 
reinforcing effects and the development of physical dependence on opiate drugs.
 
2,15
  Stimulants, such as cocaine, block the reuptake of dopamine in the synapse, 
resulting in prolonged availability of the neurotransmitter.  Studies have shown 
that increased levels of dopamine are consistent with addiction, while reduced 
levels of dopamine are consistent with a reduction in drug self administration.
 15
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Figure 4. Examples of CB1 Receptor Antagonists 
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CB1 receptor antagonists (Figure 4), such as SR-141716 [Rimonabant (8)],  
AM251 (9), and azetidine derivatives (10,11) bind to CB1 receptors and block the 
effects of CB1 agonists.
16
  These compounds are potent and selectively inhibit the 
effects of some cannabinoid agonist, such as Δ9-THC.  CB1 receptor antagonists 
block inhibition of adenlyl cyclase activity and block [
35S]GTPγS binding 
stimulation.
17,18
  Rimonabant’s profile also includes inverse agonist activity which 
is characterized by inhibition of [
35S]GTPγS binding and a decrease in K+ ion 
currents.
 17,18
  Clinical trials with Rimonabant (8) showed increased anxiety and 
depression in patients, which led to an increased incidence of suicide.
5
  Due to the 
negative effects of this drug, CB1 antagonists that have inverse agonist properties, 
may not be ideal medicinal targets.   
In lieu of the results with Rimonabant, it has been suggested that a neutral 
cannabinoid receptor antagonists (Figure 5) would be a better target because of 
potentially reduced side effects.
19,20
  However, to date neutral antagonists, such as 
arylimidazolidinone (12) and triazole LH21 (13), are less common and typically 
exhibit low potency at CB receptors.
21
   To this end, it was the goal of this research 
8 
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 Figure 5. Examples of CB1 Receptor Neutral Antagonists 
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to design, synthesize and develop potential CB1 receptors that exhibit a neutral 
cannabinoid antagonists pharmacological profile.  The availability of a high 
affinity, potent, neutral CB1 antagonist would undoubtedly prove to be a useful 
pharmacological tool to study a variety of cannabinoid mediated mechanisms and 
disease states.     
Results and Discussion 
Development of Azetidine-Based Cannabinoid Antagonists: Design Rationale 
The patent literature has reported that N-benzhydryl azetidines exhibit CB1 
antagonist activity. 
22
  However, synthetic routes and biological data supporting 
these claims are not well documented.   The known cannabinoid antagonist 
azetidine derivative 10 was identified as a lead compound to serve as a guide for 
the development of potential targets.   
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Figure 6. Pharmacophore Regions of N-Benzhydrylazetidine 
3
  
There is no reported structural-activity data for the series of azetidines represented 
by 10.  Therefore it was of interest to explore pharmacophore of 10 and develop 
novel compounds that exhibit high affinity and potency at cannabinoid receptors.  
The pharmacophore of 10 is composed of three major regions: the N-benzhydryl 
region (N-Ar region), the aryl substitute region (Aryl region) and the sulfonyl 
group region (S region).  The focus of this research was to prepare a library of 
novel compounds based upon pharmacophore of 10.  To this end, a series of N-
benzhydryl-3-benzyloxyazetidine derivatives were envisaged.  The proposed 
syntheses of these series are shown below in Scheme 1.   
10 
 
N O
X
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N
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Scheme 1.  Proposed Synthesis of 18 
22
 
The bioisosteric analogues 18, were envisaged to establish the role of the sulfonyl 
region for molecular-receptor recognition (H-bonding) and molecular lipophilicity.  
These new compounds will be used to determine optimal structural features and 
substitution patterns for the N-Ar region and S region of the azetidine targets.   
Synthesis of Azetidines 
Initially the N-4,4’-disubstitutedbenzhydryl azetidinones (15) were envisioned to 
be made using the sequence shown in Scheme 2 based upon previous work in our 
laboratories.
22-24
  Hexamethylenetetramine (20) was treated with 2,3-
dibromopropene and 2-bromopropeneamine (21) was isolated in good yields (80-
96%).  The bromopropeneamine was then brominated and 2,2,3-tribromopropyl 
amine HBr (22) was isolated (85% yield).  The tribromoamine was reacted with a 
series of 4,4’-disubstituted benzophenone derivatives and imines 23 a-e were 
isolated in good yields (Table 1).     
11 
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Scheme 2. Proposed Synthesis of N-4,4’-Disubstituted Benzhydryl Azetidines 22-24  
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       Table 1. Tribromopropylimine Derivatives 
Br N
Br Br
X
Z
Y
23
 
entry X Y Z Yield % 
23a H H H 99 
23b Cl Cl H 70 
23c F F H 71 
23d Me Me H 72 
23e OMe OMe H 76 
 
The imines 23 were treated with sodium borohydride and methanol to form the 
corresponding azetidines 24.  However, despite numerous attempted reaction 
conditions the azetidine ring wasn’t formed.  Presumably, the increased steric bulk 
of the benzhydryl moiety prevents the cyclization from occurring.      
 
 
      
 
13 
 
   Table 2.  N-Benzhydryl Azetidines 
N
X
Y
O
Z
 
entry  X Y Z Yield % 
32a H H H 75 
32b Cl Cl H 67 
32c F F H 60 
32d Me Me H 70 
32e OMe OMe H 65 
32f Cl OMe H 62 
32g F OMe H 69  
32h Cl Cl Cl 65 
 
To prepare 18, a different pathway to the N-benzhydryl azetidine reported by 
Hillier was investigated.
25
  The azetidine ring system was synthesized from 1,3-
disubstituted azetidines through the alkylation of primary amines with the bis-
triflate of a 2-substituted-1,3-propanediol derivative (Scheme 3).
25
  One of the 
reactions involved 2-oxybenzyl-1,3-propanediol (28) reacting with benzhydryl 
amine (30a) to form azetidine (31) in high yield (92%).
25
  This reaction was 
14 
 
repeated (Scheme 4) and the target compound (31) was isolated in good yield 
(75%).            
HO OH
R1
Tf2O, DIEA
ACN, -20C
TfO OTf
R1
R2NH2
DIEA
N
R1
R2
25 26
27  
Scheme 3. Proposed Synthesis of 1,3-Disubstiuted Azetidines (18)
 25   
HO OH
OBn
Tf2O, DIEA
ACN, -20C
TfO OTf
OBn
DIEA
Benzhydryl Amine
N
OBn
28 29
31
30a
 
Scheme 4. Synthesis of Benzhydryl Azetidines (31) 
25
 
Due to the efficiency of this reaction, the route illustrated in Scheme 4 was used to 
make the azetidine derivatives 32 (Table 2) from different amine bases (30b-h).  
Benzhydryl amine 30a is commercially available, but the other amine starting 
materials had to be synthesized from the various 4,4’-disubstituted benzophenone 
derivatives.  Therefore, in order to pursue a structure activity study in this system, 
a convenient method for the preparation of the desired benzhydrylamines was 
investigated.  
15 
 
Synthesis of Benzhydryl Amine Derivatives 
The first method involved forming an imine 34b-e by treating 4,4’-disubstituted 
benzophenone derivatives with ammonia, followed by reduction to the 
corresponding amine.  Unfortunately, the desired benzhydryl amines were not 
isolated in good yields using this approach (Scheme 5), so an alternative method 
was explored involving the conversion of an oxime into an amine (Scheme 6).  
NH2
X
Z
Y
NH
X
Z
Y
O
X
Z
Y
NH3
NaBH4
33 34 30
X
 
Scheme 5. Attempted Synthesis of Disubstituted N-Benzhydryl Amines through an 
Imine Intermediate (34)
26
NOH
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NH2OH
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II. NaBH4/TiCl4
33 35 30
 
Scheme 6. Synthesis of Disubstituted N-Benzhydryl Amines through an Oxime 
Intermediate (35)
27
 
The disubstituted benzophenone derivatives 33b-e were treated with 
hydroxylamine·HCl and crystallized to afford the corresponding oximes 35b-e in 
16 
 
good yields (60-90%).  This reaction worked well and once crystallized the oximes 
were reduced by catalytic hydrogenation or with NaBH4 and TiCl4, to furnish the 
benzhydryl amines 30b-e in good yields (63-86%). 
Table 3.  Benzhydryl Oxime and Amine Derivatives 
  
Entry 
 
X 
 
Y 
 
Z 
Oxime (35) 
% Yield 
Amine (30) 
% Yield 
a H H H - - 
b Cl Cl H 87 73 
c F F H 79 66 
d Me Me H 80 78 
e OMe OMe H 90 86 
f Cl OMe H 60 68 
g F OMe H 75 63 
h Cl Cl Cl 66 70 
                            
The 4,4’-disubstituted benzophenone derivatives 33f-h were not commercially 
available, so the target amines required synthesis via alternative routes.  The first 
approach was to use a Grignard method (Scheme 7). 
26
  This method involved 
reacting the corresponding Grignard reagent and a nitrile to form an imine 
followed by concomitant NaBH4 reduction to yield the desired amine 38. 
 
17 
 
MgBr
OCH3
CN
X
+
NH2
H3CO X
1) Et2O
2) NaBH4, MeOH (dry)
36 37 38
(X= F, Cl)
 
Scheme 7. Attempted Synthesis of Disubstituted Benzhydryl Amine (38)
 26 
The Grignard reagent, 4-methoxyphenylmagnesium bromide (36) was reacted with 
4-chlorobenzonitrile (37) in ether, then methanol was added to form the imine (34), 
followed by reduction with NaBH4.  Unfortunately the desired amine was not 
isolated.  This method was repeated using 4-fluorobenzonitrile with similar poor 
results.  
Using an alternative approach, the syntheses of 33f, 33g and 33h was achieved by 
reacting a Grignard reagent with the corresponding aldehyde (Scheme 8) to form 
the desired benzhydryl alcohol derivatives (40f-h), which could then be oxidized to 
the benzophenone derivatives (33f-g).  These derivatives could then be converted 
into the corresponding oximes (35) and benzhydrylamines (30) using the approach 
successfully employed previously (Scheme 6).        
18 
 
+
MgBr
X OCH3
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39 36 40f-g
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Scheme 8.  Synthesis of Disubstituted and Trisubstituted Benzophenone 
Derivatives
28, 29
 
The benzophenones 33f-h were treated with hydroxyl amine and converted into an 
oxime followed by treatment with NaBH4 and TiCl4 resulting in benzhydryl 
amines 30f-h (Table 3).  With the substituted benzhydrylamines in hand, the 
azetidine derivatives 32f-h were prepared using the bis-triflate method described 
previously (Table 2).  As illustrated in Scheme 4, the substituted benzhydryl 
azetidines were synthesized in good yield from 2-oxybenzyl-1,3- propanediol.   
Synthesis of 2-Benzyloxy Glycerol Derivatives 
With the benzhydrylamine derivatives in hand, it was also of interest to develop an 
approach for the preparation of new 2-substituted-1,3-propanediol derivatives 50.    
19 
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Scheme 9. Proposed Synthesis of 2-Substituted-1,3-Propanediol Derivatives (50)
30-
32 
Glycerol (43) was used as the starting material to make the diol analogs and tert-
Butyldiphenylsilyl chloride (TBDPSCl) was used to selectively protect the two 
primary alcohols of 43.
 30
  Once the primary alcohols were protected, the 4-
substituted benzyl group 45 was added to the secondary alcohol followed by 
treatment of tetrabutyl ammonium fluoride (TBAF) to remove the protecting 
groups.
31,32
  This afforded the corresponding 2-benzyl glycerols 50 in good overall 
yield (Table 4).  
 
 
20 
 
  Table 4. 2-Benzyloxy Glycerol Derivatives 
HO
OHO
A
50  
Entry A Yield % 
50a Me 70 
50b OMe 77 
50c Cl 60 
50d F 66 
  
This method was successful on a small scale, but further attempts to scale-up the 
reaction were problematic due to the formation of a by-product at the deprotection 
stage.  Numerous attempts were made to purify the diol intermediates but 
separation proved to be difficult.  Various columns were run on each of the crudes, 
including: 3-25% hexane/ethyl acetate; 100% hexane; 33% ethyl ether/petroleum 
ether; 100% ethyl ether; 5-10% methanol/chloroform and 100% methanol.  
Unfortunately, none of these chromatographic conditions afforded the glycerol 
derivatives in sufficient purity to be synthetically useful.  
Alternative methods were used in an attempt to remove the tert-butyldiphenylsilyl 
group (Scheme 10).  One method involved each of the protected diols being 
21 
 
dissolved in methanol and treated with varying concentrations (10-100%) of HCl at 
room temperature.
 33
  Numerous columns were run on the crudes and a by-product 
was still present.  Another method involved each of the protected diols being 
dissolved in dry methanol and treated with a catalytic amount of acetyl chloride 
(AcCl) at room temperature.
 34
  10% ethyl acetate/hexane was used to remove the 
byproduct and 5% methanol/chloroform was used to isolate the product in small 
yields.      
OTBDPS
OTBDPS
O
A
OH
OH
O
A
10-100% HCl
MeOH, rt
46 50
overnight
+ byproduct
OTBDPS
OTBDPS
O
A
OH
OH
O
A
AcCl (.3 eq)
dry MeOH, rt
46 50
overnight
+ byproduct
 
Scheme 10 : Synthesis of 2-Substituted-1,3-Propanediol Derivatives (50)
 33,34
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A better method of producing the substituted 2-benzyoxy-1,3-propane diols was 
employed using a 1,3-dioxane derivative.
35  
This could be done on a larger scale 
and involved only two steps.  However, 2-phenyl-1,3-dioxan-5-ol (47) was slightly 
more expensive than tert-butyldimethylsilyl chloride.   
O O
OH
O O
O
1) KOH, THF
0°C
2)
(A= Cl, F, OMe, Me)
overnight
Br
A
HO OH
O
A
10% HCl, THF
reflux 2-6 hours
A
65-84%
80-92%
47 48
49
50
 
Scheme 11 . Synthesis of Substituted 2-Benzyloxy-1,3-Propane Diols (50)
35
 
The reaction involved reacting 2-phenyl-1,3-dioxan-5-ol (47) with potassium 
hydroxide and substituted benzyl bromides (48).
35
  The corresponding substituted 
5-benzyloxy-2-phenyl-[1,3]dioxanes (49) were hydrolyzed to the diols (50) in 
good yields (80-92%).  
Cannabinoid Receptor Affinity 
The binding affinities of the azetidines derivatives (Table 5) were determined by 
the inhibition of [
3
H]SR141716 binding in homogenates of rat cerebellum 
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(Breivogel et al., 1997).  For each compound, each concentration was tested in 
triplicate and each experiment was replicated three times.   
Table 5. Cannabinoid Receptor Affinity 
N
X
Y
O
 
 
Compound
a
 
 
X 
 
Y 
% inhibition 
@10 M 
% inhibition  
@100 M 
32a H H 11 43 
32b Cl Cl 38 77 
32c F F 12 36 
32e OCH3 OCH3 0 18 
          a
All compounds were tested as the oxalate salt. 
In general, N-benzhydryl-3-benzyloxyazetidines exhibited low affinities (IC50 
values would be > 10 µM).  The dichloro analogue 32b was the most potent 
compound of the series and exhibited 77% inhibition of [
3
H]SR141716 at 100 µM.  
However, at a lower concentration of 10 µM, only 38% inhibition of 
[
3
H]SR141716 was observed.  Both the unsubstituted analog 32a and the difluoro 
analog 32c exhibited affinities less than 32b, while the dimethoxy analog 32e was 
nearly inactive.     
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Conclusion 
A series of N-benzhydryl-3-benzyloxyazetidines were synthesized from 
commercially available 2-benzyloxy glycerol and a series of substituted 
benzhydryl amines.  The N-benzhydryl-3-benzyloxyazetidines were obtained in 
good overall yields.  In general, the N-benzhydryl-3-benzyloxyazetidines exhibited 
modest to low affinity for cannabinoid receptors.  However, it appears that 
modification of the benzhydryl group can lead to improved receptor affinity.  In 
addition, a series of substituted benzyloxy derivatives were prepared from 2-
phenyl-1,3-dioxan-5-ol.  The availability of novel substituted 2-benzyloxy glycerol 
will be useful for future structure-activity studies with the N-benzhydryl-3-
benzyloxyazetidine derivatives.  
Experimental Section 
All the chemicals were purchased from Aldrich Chemical Co., Milwaukee, WI, 
unless otherwise noted.  Anhydrous THF was purchased from Mallindkrodt Baker.  
Anhydrous solvents toluene, dimethylformamide and acetonitrile were purchased 
from VWR International Co. and were used under argon without further 
purification.  Chromatography refers to column chromatography on silica gel 
(Silica Gel 60, 230-400 mesh).  Reported melting points are uncorrected.  NMR 
spectra were recorded on a Varian-Gemini 400 MHz spectrometer.  Chemical 
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shifts are reported in δ values with tetramethylsilane (TMS), employed as the 
internal standard.  Elemental analyses were obtained from Atlantic Microlabs, Inc., 
Norcross, GA.    
Br
NH2 
2-Bromopropeneamine (21). 
In a three-neck flask, hexamethylenetetramine (63 g, 0.45 mol, 1.1 eq) was 
dissolved in CHCl3 (600 mL).  The solution was allowed to reflux and 2,3-
dibromopropene (100 g, 0.50 mol, 1.0 eq) was added drop-wise over an hour.  The 
reaction mixture was heated to reflux for 3 hours and allowed to stand overnight.  
The solution was cooled in ice bath, salt was collected by vacuum filtration and the 
yellow crude 2-bromoallylhexanimium was placed in a 4L beaker to air dry 
overnight.  The 2-bromo-allyl hexaminium bromide (150 g, 0.58 mol) was 
collected and added to a warm solution of EtOH (2L), H2O (400 mL) and 12 N 
HCl (480 mL).  The mixture was stirred until all the solids had dissolved and let 
stand for 24 hours.  The precipitate was collected using vacuum filtration and the 
liquid was evaporated to dryness.  The residue was dissolved in H2O (300 mL) and 
the pH was adjusted to pH = 10 with 6 N NaOH.  The red-brown oil was separated 
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in a seperatory funnel and the aqueous layer was extracted with ethyl ether (3 x 
100 mL).  The combined oil and ether extracts were washed with saturated NaCl 
(50 mL) and dried over potassium carbonate.  The solution was filtered and 
concentrated under reduced pressure to afford 2-bromopropeneamine (26 g, 83%).  
Mp 183-186 ºC [lit. mp 184-186 ºC].
23
  
1
H NMR (400 MHz, CDCl3) δ 5.78 (s, 1H),  
5.48 (s, 1H), 3.48 (s, 2H), 1.60 (s, 2H).
23
 
Br NH2 HBr
Br Br  
2,2,3-Tribromopropyl amine HBr (22).  
2-Bromoallylamine (22.1 g, 0.163 mol, 1 eq) was dissolved in H2O and 48% HBr 
(25 mL, 0.179 mol, 1.1 eq) was added slowly, followed by bromine (13 mL, 0.243 
mol, 1.5 eq).  This mixture was allowed to stir overnight and was then concentrated 
under reduced pressure.  The solution was treated with solid sodium thiosulfate 
until colorless.  Solid formed and 2,2,3-tribromopropyl amine HBr was confirmed 
by NMR (52 g, 85%).  Mp 196-198 ºC  [lit. mp 196-198 ºC].
 24
  
1
H NMR (400 
MHz, D2O) δ 4.35 (s, 2H), 3.82 (s, 2H), 2.0 (s, 3H).
24
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Br N
Br Br
 
General Method A. 2,2,3-Tribromo-N-(diphenylmethylene)propan-1-amine 
(23a).   
Tribromopropyl amine HBr (1.17 g, 3.11 mmol, 1 eq), CH2Cl2 (20 mL), Et3N (5 
mL) and benzophenone (0.57 g, 3.13 mmol, 1 eq) were added to a 100 mL round 
bottom flask.  The mixture was stirred for an hour, then H2O (2 mL) was added and 
the mixture was stirred for an additional hour.  The solution was extracted with 
CH2Cl2 (2 x 10 mL), dried over magnesium sulfate and concentrated using low 
heat under reduced pressure.  A yellowish-white solid formed and 2,2,3-tribromo-
N-(diphenylmethylene)propan-1-amine was confirmed by NMR (1.4 g, 99%).  
1
H 
NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8 Hz, 2H), 7.58 (t, J = 8 Hz, 3H), 7.48- 
7.44 (m, 5H), 4.22 (s, 2H), 3.39 (s, 2H).
24
  
Br N
Br Br
Cl Cl  
N-(Bis(4-chlorophenyl)methylene)-2,2,3-tribromopropan-1-amine (23b).   
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Synthesized using General Method A and 4,4’-dichlorobenzophenone to yield a 
light orange solid (2.0 g, 70%).  
1
H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 4 Hz, 
4H), 7.63 (d, J = 4 Hz, 4H), 4.41 (s, 2H) 3.27 (s, 2H). 
Br N
Br Br
F F  
N-(Bis(4-fluorophenyl)methylene)-2,2,3-tribromopropan-1-amine (23c). 
Synthesized using General Method A and 4,4’-difluorobenzophenone to yield a 
yellowish solid (0.99 g, 71%).  
1
H NMR (400 MHz, CDCl3) δ 7.82-7.78 (m, 4H), 
7.40-7.30 (m, 4H), 4.41 (s, 2H), 3.29 (s, 2H). 
Br N
Br Br
 
N-(Bis(4-methylphenyl)methylene)-2,2,3-tribromopropan-1-amine (23d). 
Synthesized using General Method A and 4,4’-dimethylbenzophenone to yield a 
yellowish solid (2.1 g, 72%).  
1
H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 4 Hz, 
4H), 7.30 (d, J = 4 Hz, 4H), 4.29 (s, 2H), 3.40 (s, 2H), 2.41 (s, 6H).  
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Br N
Br Br
OO  
N-(Bis(4-methoxyphenyl)methylene)-2,2,3-tribromopropan-1-amine (23e).  
Synthesized using General Method A and 4,4’-dimethoxybenzophenone to yield a 
yellowish solid (2.0 g, 76%).  
1
H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 4 Hz, 
4H), 7.05 (d, J = 4 Hz, 4H), 4.41 (s, 2H), 3.82 (s, 6H), 3.27 (s, 2H).  
N O
 
General Method B.  Benzhydryl-3-(benzyloxy)azetidine (32a).  
Under nitrogen, 2-oxybenzyl-1,3-propanediol (0.20 g, 1.05 mmol, 1.05 eq) was 
added to dry acetonitrile (10 mL) at 20 ºC.  Tf2O (0.39 mL, 2.30 mmol, 2.2 eq) was 
added slowly over 10-20 minutes, maintaining temperature below 10 ºC.   DIEA 
(0.47 mL, 2.71 mmol, 2.6 eq) was added over 10-20 minutes maintaining 
temperature below 10 ºC.  The mixture was allowed to stir for 10 minutes and 
DIEA (0.47 mL, 2.71 mmol, 2.6 eq) was added to the mixture over 5 minutes.  
Benzhydrylamine (0.18 mL, 1.10 mmol, 1.1 eq) was added over 5 minutes and the 
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reaction was heated to 70 ºC for 1-2 hours.  The reaction was allowed to cool and 
the crude solid was purified via column chromatography (SiO2) with 10% ethyl 
acetate/90% hexane column.  Benzhydryl-3-(benzyloxy)azetidine was confirmed 
by NMR (0.26 g, 75%) as an oil.  
1
H NMR (400 MHz, CDCl3) δ 7.48-7.45 (m, 
4H), 7.39-7.30 (m, 9H), 7.27-7.17 (m, 2H), 4.46 (s, 2H), 4.43 (s, 1H), 4.32-4.27 
(m, 1H), 3.57 (dd, J = 6.1, 8.7 Hz, 1H), 3.57 (dd, J = 4.1, 6.7 Hz, 1H), 3.02 (dd, J = 
6.1, 8.7 Hz, 1H), 3.02 (dd, J = 4.1, 6.7 Hz, 1H).
25 
 Anal. (C23H23NO·C2H2O4·½ 
H2O): C, 71.58; H, 6.01; N, 3.34.  Found: C, 71.08; H, 5.97; N, 3.35. 
N O
Cl
Cl  
3-(Benzyloxy)-1-(bis(4-chlorophenyl)methyl)azetidine (32b).    
Synthesized using General Method B and Bis(4-chlorophenyl)methyl amine to 
yield a brown oil.  The oxalate salt was obtained by dissolving the azetidine in 
acetone and oxalic acid (0.42 g, 67%).  
1
H NMR (400 MHz, CDCl3) δ 7.48-7.37 
(m, 8H), 7.38-7.30 (m, 5H), 4.49 (s, 2H), 4.41 (s, 1H), 4.32-4.27 (m, 1H), 3.58 (dd, 
J=6.1, 8.7 Hz, 1H), 3.58 (dd, J=4.1, 6.7 Hz, 1H), 3.02 (dd, J=6.1, 8.7 Hz, 1H), 3.02 
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(dd, J=4.1, 6.7 Hz, 1H).  Anal. (C23H21Cl2NO·C2H2O4·½ H2O): C, 61.48; H, 4.75; 
N, 2.87.  Found: C, 62.14; H, 5.12; N, 2.79.   
N O
F
F  
3-(Benzyloxy)-1-(bis(4-fluorophenyl)methyl)azetidine (32c).   
Synthesized using General Method B and Bis(4-fluorophenyl)methyl amine to 
yield a brown oil.  The oxalate salt was obtained by dissolving the azetidine in 
acetone and oxalic acid (0.34 g, 60%).  
1H NMR (400 MHz, CDCl3) δ 7.50-7.30 
(m, 4H), 7.22-7.13 (m, 6H), 7.10-6.95 (m, 3H), 4.44 (s, 2H), 4.43 (s, 1H), 4.32-
4.25 (m, 1H), 3.58 (dd, J=6.1, 8.7 Hz, 1H), 3.58 (dd, J=4.1, 6.7 Hz, 1H), 3.02 (dd, 
J=6.1, 8.7 Hz, 1H), 3.02 (dd, J=4.1, 6.7 Hz, 1H).  Anal. (C23H23F2NO·C2H2O4·½ 
H2O): C, 64.07; H, 5.22; N, 2.99.  Found: C, 64.49; H, 5.14; N, 2.88. 
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N O
 
3-(Benzyloxy)-1-(bis(4-methylphenyl)methyl)azetidine (32d).  
Synthesized using General Method B and Bis(4-methylphenyl)methyl amine to 
yield a brown oil.  The oxalate salt was obtained by dissolving the azetidine in 
acetone and oxalic acid (0.39 g, 70%).  
1
H NMR (400 MHz, CDCl3) δ 7.48-7.40 
(m, 4H), 7.36-7.28 (m, 6H), 7.26-7.21 (m, 3H), 4.41 (s, 2H), 4.39 (s, 1H), 4.27-
4.21 (m, 1H), 3.52 (dd, J=6.1, 8.7 Hz, 1H), 3.52 (dd, J=4.1, 6.7 Hz, 1H), 2.98 (dd, 
J=6.1, 8.7 Hz, 1H), 2.98 (dd, J=4.1, 6.7 Hz, 1H), 2.37 (s, 6H).  
N O
O
O  
3-(Benzyloxy)-1-(bis(4-methoxyphenyl)methyl)azetidine (32e).  
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Synthesized using General Method B and Bis(4-methoxyphenyl)methyl amine to 
yield a brown oil.  The oxalate salt was obtained by dissolving the azetidine in 
acetone and oxalic acid (0.40 g, 65%).  
1
H NMR (400 MHz, CDCl3) δ 7.41-7.29 
(m, 8H), 6.90-6.80 (m, 5H), 4.41 (s, 2H), 4.37 (s, 1H), 4.31-4.24 (m, 1H), 3.77 (s, 
6H), 3.59 (dd, J=6.1, 8.7 Hz, 1H), 3.59 (dd, J=4.1, 6.7 Hz, 1H), 3.02 (dd, J=6.1, 
8.7 Hz, 1H), 3.02 (dd, J=4.1, 6.7 Hz, 1H).  Anal. (C23H23NO·C2H2O4·½ H2O): C, 
67.63; H, 6.10; N, 2.92.  Found: C, 67.71; H, 6.10; N, 2.92.   
N O
Cl
O  
3-(Benzyloxy)-1-((4-chlorophenyl)(4-methoxyphenyl)methyl)azetidine (32f).    
Synthesized using General Method B and (4-chlorophenyl)(4-methoxyphenyl) 
methanamine to yield a brown oil.  The oxalate salt was obtained by dissolving the 
azetidine in acetone and oxalic acid (0.15 g, 62%).  
1
H NMR (400 MHz, CDCl3) δ 
7.36-7.21 (m, 11H), 6.82-6.78 (m, 2H), 4.40 (s, 2H), 4.29 (s, 1H), 4.24-4.18 (m, 
1H), 3.73 (s, 3H), 3.50 (dd, J=6.1, 8.7 Hz, 1H), 3.50 (dd, J=4.1, 6.7 Hz, 1H), 2.93 
(dd, J=6.1, 8.7 Hz, 1H), 2.93 (dd, J=4.1, 6.7 Hz, 1H).  
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N O
F
O  
3-(Benzyloxy)-1-((4-fluorophenyl)(4-methoxyphenyl)methyl)azetidine (32g).   
Synthesized using General Method B and (4-fluorophenyl)(4-methoxyphenyl) 
methanamine to yield a brown oil.  The oxalate salt was obtained by dissolving the 
azetidine in acetone and oxalic acid (0.27 g, 69%).  
1
H NMR (400 MHz, CDCl3) δ 
7.43-7.23 (m, 11H), 6.96-6.82 (m, 2H), 4.40 (s, 2H), 4.37 (s, 1H), 4.31-4.26 (m, 
1H), 3.75 (s, 3H), 3.51 (dd, J=6.1, 8.7 Hz, 1H), 3.51 (dd, J=4.1, 6.7 Hz, 1H), 2.95 
(dd, J=6.1, 8.7 Hz, 1H), 2.95 (dd, J=4.1, 6.7 Hz, 1H). 
N O
Cl
Cl
Cl
 
3-(Benzyloxy)-1-((4-chlorophenyl)(3,4-dichlorophenyl)methyl)azetidine (32h).   
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Synthesized using General Method B and (4-chlorophenyl)(3,4-dichlorophenyl) 
methanamine to yield a brown oil.  The oxalate salt was obtained by dissolving the 
azetidine in acetone and oxalic acid (0.30 g, 65%).  
1
H NMR (400 MHz, CDCl3) δ 
7.50-7.18 (m, 12H), 4.41 (s, 2H), 4.30 (s, 1H), 4.24-4.18 (m, 1H), 3.46 (dd, J=6.1, 
8.7 Hz, 1H), 3.46 (dd, J=4.1, 6.7 Hz, 1H), 2.91 (dd, J=6.1, 8.7 Hz, 1H), 2.91 (dd, 
J=4.1, 6.7 Hz, 1H).  
NOH
Cl Cl  
General Method C.  Bis(4-chlorophenyl)methanone oxime (35b).  
A solution of Bis(4-chlorophenyl)methanone (4.00 g, 0.016 mol, 1 eq), 
NH2OH·HCl (3.32 g, 0.048 mol, 3 eq) and Na2CO3 (5.07 g, 0.048 mol, 3 eq) in 
ethanol (70 mL) was stirred and heated to reflux for 6 hours.  The solvent was 
concentrated under reduced pressure and the residue dissolved in an aqueous 
solution of potassium carbonate and filtered thru suction filtration.  The resulting 
crystalline residue was dissolved in CH2Cl2, filtered and the solvent concentrated 
under reduced pressure.  The crude was crystallized from hot methanol and bis(4-
chlorophenyl)methanone oxime was confirmed by NMR (3.7 g, 87%).  Mp 137 ºC 
[lit. mp 138 ºC].
27
  
1
H NMR (400 MHz, DMSO) δ 7.37 (d, J=8 Hz, 4H), 7.29 (d, 
J=8 Hz, 4H).
27
 
36 
 
NOH
F F  
Bis(4-fluorophenyl)methanone oxime (35c).  
Synthesized using General Method C from Bis(4-fluorophenyl)methanone and the 
oxime was crystallized using hot methanol (3.4 g, 79%).  Mp 142 ºC [lit. mp 142 
ºC].
27
  
1
H NMR (400 MHz, DMSO) δ 7.43-7.10 (m, 8H).27 
NOH
 
Bis(4-methylphenyl)methanone oxime (35d).  
Synthesized using General Method C from Bis(4-methylphenyl)methanone and the 
oxime was crystallized using hot methanol (1.7 g, 80%).  Mp 167 ºC [lit. mp 168 
ºC].
27
  
1
H NMR (400 MHz, DMSO) δ 7.27 (d, J = 8 Hz, 4H), 7.20 (d, J = 8 Hz, 
4H), 2.38 (s, 6H).
27
 
NOH
O O  
Bis(4-methoxyphenyl)methanone oxime (35e).  
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Synthesized using General Method C from Bis(4-methoxyphenyl)methanone and 
the oxime was crystallized using hot methanol (3.8 g, 90%).  
1
H NMR (400 MHz, 
DMSO) δ 7.25 (d, J = 4 Hz, 4H), 6.80 (d, J = 4 Hz, 4H), 3.75 (s, 6H). 
NOH
Cl O  
(4-Chlorophenyl)(4-methoxyphenyl) methanone oxime (35f).  
Synthesized using General Method C from (4-chlorophenyl)(4-methoxyphenyl) 
methanone and the oxime was crystallized using hot methanol (0.24 g, 60%).  
1
H 
NMR (400 MHz, DMSO) δ 7.42-7.21 (m, 4H), 7.00 (d, J = 4 Hz, 2H), 6.80 (d, J = 
4Hz, 2H), 3.81 (s, 3H).   
NOH
F O  
(4-Fluorophenyl)(4-methoxyphenyl) methanone oxime (35g).  
Synthesized using General Method C from (4-fluorophenyl)(4-methoxyphenyl) 
methanone and the oxime was crystallized using hot methanol (0.32 g, 75%).  
1
H 
NMR (400 MHz, DMSO)  δ 7.40-7.33 (m, 4H), 6.93-6.89 (m, 4H), 3.83 (s, 3H).     
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NOH
Cl
Cl
Cl
 
(4-Chlorophenyl)(3,4-dichlorophenyl) methanone oxime (35h).  
Synthesized using General Method C from (4-chlorophenyl)(3,4-dichlorophenyl) 
methanone and the oxime was crystallized using hot methanol (1.2 g, 66%).  
1
H 
NMR (400 MHz, DMSO) δ 7.50-7.15 (m, 7H).    
NH2
Cl Cl  
General Method D.  Bis(4-chlorophenyl)methyl amine (30b).  
General Method D.  NaBH4 (1.57 g, 0.042 mol, 4.1eq) was added to a solution of 
bis(4-chlorophenyl)methanone oxime (2.70 g, 0.010 mol, 1 eq) in 1,2 
dimethoxyethane (10 mL) and TiCl4 (4.04 g, 0.021 mol, 2.1 eq) was added slowly 
under nitrogen atmosphere at 0 ºC.  The solution was warmed to room temperature 
and stirred for 24 hours.  Cold water (100 mL) was added and the solution was 
adjusted to pH = 10 with ammonia.  The solution was then extracted with ethyl 
acetate and the organic layer was washed with saturated NaCl solution, dried over 
sodium sulfate and concentrated under reduced pressure.  Bis(4-
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chlorophenyl)methyl amine was crystallized as a hydrochloride salt from 
ethanol/ethyl ether (1.8 g, 73%).  [lit. mp 262 ºC].
27  1
H NMR (400 MHz, DMSO) δ 
7.39 (d, J=8 Hz, 4H), 7.31 (d, J=8 Hz, 4H), 5.10 (s, 1H).
27
 
NH2
F F  
Bis(4-fluorophenyl)methyl amine (30c).   
Synthesized from General Method D using Bis(4-fluorophenyl)methanone oxime 
and the amine was crystallized as a hydrochloride salt from ethanol/ethyl ether (2.0  
g, 66%).  [lit. mp 250 ºC].
27
  
1
H NMR (400 MHz, DMSO) δ 7.48-7.03 (m, 8H), 
5.20 (s, 1H).
27
 
NH2
 
Bis(4-methylphenyl)methyl amine (30d).  
Synthesized from General Method D using Bis(4-methylphenyl)methanone oxime 
and the amine was crystallized as a hydrochloride salt from ethanol/ethyl ether (1.1 
g, 78%).  [lit. mp 246 ºC].
27
  
1
H NMR (400 MHz, DMSO) δ 7.28 (d, J=8.0 Hz, 
4H), 7.18 (d, J=8.0 Hz, 4H), 5.20 (s, 1H), 2.38 (s, 6H).
27 
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NH2
O O  
Bis(4-methoxyphenyl)methyl amine (30e).  
 Synthesized from General Method D using Bis(4-chlorophenyl)methanone oxime 
and the amine was crystallized as a hydrochloride salt from ethanol/ethyl ether (2.1 
g, 86%).  
1
H NMR (400 MHz, DMSO) δ 7.28 (d, J = 4 Hz, 4H), 6.81 (d, J = 4Hz, 
4H), 5.01 (s, 1H). 3.71 (s, 6H).  
NH2
Cl O  
(4-Chlorophenyl)(4-methoxyphenyl)methanamine (30f).  
Synthesized from General Method D using (4-chlorophenyl)(4-
methoxyphenyl)methanone oxime and the amine was crystallized as a 
hydrochloride salt from ethanol/ethyl ether (0.16 g, 68%).  
1
H NMR (400 MHz, 
DMSO) δ 7.39-7.13 (m, 4H), 6.93-6.80 (m, 4H), 5.17 (s, 1H), 3.81 (s, 3H).  
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NH2
F O  
(4-Fluorophenyl)(4-methoxyphenyl)methanamine (30g).  
Synthesized from General Method D using (4-fluorophenyl)(4-
methoxyphenyl)methanone oxime and the amine was crystallized as a 
hydrochloride salt from ethanol/ethyl ether (0.19 g, 63%).  
1
H NMR (400 MHz, 
DMSO)  δ 7.41-7.32 (m, 4H), 6.94-6.85 (m, 4H), 5.20 (s, 1H), 3.83 (s, 3H). 
NH2
Cl
Cl
Cl
 
(4-Chlorophenyl)(3,4-dichlorophenyl)methanamine (30h).  
Synthesized from General Method D using (4-chlorophenyl)(3,4-
dichlorophenyl)methanone oxime and the amine was crystallized as a 
hydrochloride salt from ethanol/ethyl ether (0.81 g, 70%).  
1
H NMR (400 MHz, 
DMSO) δ  7.51-7.13 (m, 7H), 5.17 (s, 1H). 
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OH
Cl O  
(4-Chlorophenyl)(4-methoxyphenyl)methanol (40f).   
4-Methoxyphenyl magnesium bromide (6.30 mL, 1M in THF, 1eq) was syringed 
into a flask under nitrogen.  A catalytic amount of CuI (0.006 g, 0.032 mmol) and 
4-chlorobenzaldehyde (4.0 g, 0.028 mol, 1 eq), dissolved in ethyl ether (50 mL), 
was added slowly over 5-10 minutes with stirring.  A small amount of heat was 
used for 5-10 minutes and the mixture was stirred overnight.   Ethanol (20 mL) 
was added drop wise, with stirring, followed by 3 M HCl (20 mL) in 1 mL 
increments.  The solution was extracted using HCl (3 x 20 mL) and the ether layer 
was washed with saturated NaCl solution and dried over sodium sulfate.  The 
solution was filtered and concentrated under reduced pressure.  (4-
Chlorophenyl)(4-methoxyphenyl)methanol was crystallized using hexane and 
confirmed by NMR (1.9 g, 55%).  
1
H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 4 Hz, 
2H), 7.69 (d, J = 4 Hz, 2H), 7.43 (d, J = 4 Hz, 2H), 6.98 (d, J = 4 Hz, 2H), 5.35 (s, 
1H), 3.83 (s, 3H).
28  
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OH
F O  
(4-Fluorophenyl)(4-methoxyphenyl)methanol (40g).  
4-Methoxyphenyl magnesium bromide (7.13 mL, 1 M in THF, 1eq) was syringed 
into a flask under nitrogen.   A catalytic amount of CuI (.005 g, 0.026 mmol) and 
4-fluorobenzaldehyde (1.70 g, 0.014 mol, 1eq), dissolved in dry THF (20 mL), was 
added slowly and the mixture was stirred overnight.   Ethanol (20 mL) was added 
drop wise, with stirring, followed by 3 M HCl (3 x 20 mL) in 1 mL increments.  
The solution was extracted using HCl (3 x 20 mL) and the ether layer was washed 
with saturated NaCl solution, dried over sodium sulfate, filtered using vacuum 
filtration and concentrated under reduced pressure.  (4-Fluorophenyl)(4-
methoxyphenyl)methanol was crystallized using hexane/ether and confirmed by 
NMR (1.9 g, 60%).  
1
H NMR (400 MHz, CDCl3) δ 7.49-7.38 (m, 2H), 7.30-7.23 
(m, 2H), 7.18-7.10 (m, 2H), 7.03-6.93 (m, 2H), 5.42 (s, 1H), 3.81 (s, 3H).
28
  
OH
Cl
Cl
Cl
 
(4-Chlorophenyl)(3,4-dichlorophenyl)methanol (40h).  
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4-Chlorophenyl magnesium bromide (5.56 mL, 1 M in THF, 1eq) was syringed 
into a flask under nitrogen.  A catalytic amount of CuI (0.005 g, 0.026 mmol) and 
3,4-dichlorobenzaldehyde (4.0 g, 0.023 mol, 1eq), dissolved in ethyl ether (60 
mL), was added slowly over 5-10 minutes with stirring.  A small amount of heat 
was used for 5-10 minutes and the mixture was stirred overnight.  Ethanol (20 mL) 
was added drop wise, with stirring, followed by 3 M HCl (20 mL) in 1 mL 
increments.  The solution was extracted using HCl (3 x 20 mL), washed with 
saturated NaCl solution and the ether layer was dried over sodium sulfate, filtered 
using vacuum filtration and concentrated under reduced pressure.  (4-
Chlorophenyl)(3,4-dichlorophenyl)methanol was crystallized using hexane and 
confirmed by NMR (4.3 g, 65%).  
1
H NMR (400 MHz, CDCl3)  δ 7.95-7.41 (m, 
7H), 5.41 (s, 1H).
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O
Cl O  
(4-Chlorophenyl)(4-methoxyphenyl)methanone (33f).  
PCC (0.55g, 2.53 mmol, 1.25eq) was added to (4-chlorophenyl)(4-methoxyphenyl) 
methanol (0.50 g, 2.01 mmol, 1eq) dissolved in CH2Cl2 (15 mL) and allowed to stir 
under nitrogen overnight.  The mixture was filtered through a Celite plug, rinsed 
with ethyl ether and concentrated under reduced pressure.  (4-Chlorophenyl)(4-
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methoxyphenyl)methanone was confirmed using NMR (0.31 g, 63%).  
1
H NMR 
(400 MHz, CDCl3) δ 7.81 (d, J = 4Hz, 2H), 7.70 (d, J = 4Hz, 2H), 7.44 (d, J = 4Hz, 
2H), 6.93 (d, J = 4Hz, 2H), 3.83 (s, 3H).
29
    
O
F O  
(4-Fluorophenyl)(4-methoxyphenyl)methanone (33g).  
PCC (1.70 g, 7.89 mmol, 3 eq) was added to (4-fluorophenyl)(4-methoxyphenyl) 
methanol (0.61 g, 2.63 mmol, 1eq) dissolved in CH2Cl2 (40 mL) and allowed to stir 
under nitrogen overnight.  The mixture was concentrated under reduced pressure 
and extracted using 30:70 ethyl acetate/ petroleum ether (3 x 100 mL each).  The 
solution was filtered and concentrated under reduced pressure to afford (4-
fluorophenyl)(4-methoxyphenyl)methanone (0.40 g, 66%).  
1
H NMR (400 MHz, 
CDCl3) δ 7.49-7.38 (m, 2H), 7.30- 7.23 (m, 2H), 7.18-7.10 (m, 2H), 7.03-6.93 (m, 
2H), 3.81 (s, 3H).
29 
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Cl Cl
Cl  
(4-Chlorophenyl)(3,4-dichlorophenyl)methanone (33h).  
PCC (4.97 g, 0.023 mol, 1.25eq) was added to (4-chlorophenyl)(3,4-
dichlorophenyl)methanol (2.21 g, 0.008 mol, 1eq) dissolved in CH2Cl2 (15 mL) 
and allowed to stir under nitrogen overnight.  The mixture was concentrated under 
reduced pressure and extracted using 30:70 ethyl acetate/petroleum ether (3 x 100 
mL each).  The solution was filtered and concentrated under reduced pressure to 
afford (4-chlorophenyl)(3,4-dichlorophenyl)methanone (1.5 g, 68%).  
1
H NMR 
(400 MHz, CDCl3) δ 7.93-7.19 (m, 7H).
29
     
OHHO
O
 
General Method E.  2-(4-Methylbenzyloxy)propane-1,3-diol (50a).  
2-Phenyl-1,3-dioxan-5-ol (2.50 g, 0.014 mol) was dissolved in distilled THF (60 
mL) and stirred for ten minutes.  The mixture was placed in an ice bath and finely 
ground KOH (1.77 g, 0.032 mol) was added and allowed to react for ten minutes.  
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4-Methylbenzyl chloride (2.83 mL, 0.021 mol) was added via syringe at 0 ºC and 
stirred overnight at room temperature.  H2O (30 mL) was added and the THF layer 
was concentrated under reduced pressure.  The solution was extracted with 
CH2CL2 (3 x 30 mL), dried over sodium sulfate and concentrated under reduced 
pressure.  The dioxane intermediate product was precipitated using 
ethanol/dichloromethane and evaporated to dryness.  The dioxane intermediate was 
dissolved in THF (40 mL) and 10 % aq HCl (40 mL) and allowed to reflux for 2 
hours.  The mixture was cooled to room temperature and poured over sodium 
carbonate (30 mL), followed by concentration of the THF layer.  The aqueous 
solution was extracted with CH2Cl2 (3 x 30 mL), dried over sodium sulfate and 
concentrated under reduced pressure.  2-(4-Methylbenzyloxy)propane-1,3-diol was 
precipitated using hexane and confirmed by NMR (2.6 g, 92%).  
1
H NMR (400 
MHz, CDCl3) δ 7.25 (d, J = 4 Hz, 2H), 7.18 (d, J = 4 Hz, 2H), 4.61 (s, 2H), 3.72 (d, 
J = 4 Hz, 4H), 3.61-3.52 (m, 1H), 2.36 (s, 3H).
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2-(4-Methoxybenzyloxy)propane-1,3-diol (50b).  
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Synthesized using General Method E from 4-methoxybenzyl chloride and 
precipitated using methanol (2.6 g, 90%).   
1
H NMR (400 MHz, CDCl3) δ 7.31 (d, 
J = 4 Hz, 2H), 6.91 (d, J = 4 Hz, 2H), 4.60 (s, 2H), 3.81 (s, 3H), 3.62 (d, J = 4 Hz, 
4H), 3.60-3.51 (m, 1H).  
OHHO
O
Cl
 
2-(4-Chlorobenzyloxy)propane-1,3-diol (50c).  
Synthesized using General Method E from 4-chlorobenzyl chloride and 
precipitated using ethyl acetate/hexane (2.4 g, 84%).  
1
H NMR (400 MHz, CDCl3) 
δ 7.32-7.23 (m, 4H), 4.61 (s, 2H), 3.76 (d, J = 8 Hz, 4H), 3.61-3.50 (m, 1H). 
OHHO
O
F
 
2-(4-Fluorobenzyloxy)propane-1,3-diol (50d).  
Synthesized using General Method E from 4-fluorobenzyl chloride and 
precipitated using methanol (2.3 g, 80%).   
1
H NMR (400 MHz, CDCl3) δ 7.31 (d, 
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J = 8 Hz, 2H), 7.01 (d, J = 8 Hz, 2H), 4.59 (s, 2H), 3.71 (d, J = 8 Hz, 4H), 3.58-
3.50 (m, 1H).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
References 
1) McKim, W. A., Drugs, Brain and Behavior: An Introduction to 
Behavioral Pharmacology, 4
th
 ed; Prentice Hall, New Jersey, 2000. 
2) Koob, G. F.; Le M., Neurobiology of Addiction; Academic Press, China, 
2005. 
3) Lange, J.; Kruse, C. G., Drug Discovery Today, 2005, 10, 693.   
4) Chen, J.; Han, X.; Liu, Q., J. Med. Chem. 2006, 49, 625. 
5) Huffman, J.; Zengin, G.; Wu, M.; Lu, J.; Hynd, G.; Bushell, K., Bio & 
Med. Chem. 2005, 13, 88. 
6) Deng, H.; Gifford, A.; Zvonok, A.; Cui, G.; Li, X., J. Med. Chem. 2005, 
48, 6386. 
7) Lambert, D.; Fowler, C., J. Med. Chem. 2005, 48, 5059. 
8) Devane, W. A.; Dysarz, F. A.; Johnson, M. R., Mol. Pharmacol. 1988, 
34, 605. 
9) Gloriam, D.; Foord, S.; Blaney, F; Garland, S., J. Med. Chem. 2009, 52, 
4429. 
10) Lange, J.; van Stuivenberg, H., J. Med. Chem. 2005, 48, 1823.  
11) Murineddu, G.; Ruiu, S.; Loriga, G., J. Med. Chem. 2005, 48, 7351. 
12) Khanolkar, A.; Lu, D.; Ibrahim, M.; Duclos, R., J. Med. Chem. 2007, 
50, 6493. 
13) Brizzi, A.; Brizzi, V.; J. Med. Chem. 2005, 48, 7343. 
14) Ahn, K.; McKinney, M.; Cravatt, B. F., Chem Rev. 2008, 108, 1687. 
15) Murray, J.; Bevins, R., ACS Chem. Neurosci. 2010, 1, 265. 
16) Silvestri, R.; Cascio, M.; La Regina, G., J. Med. Chem. 2008, 51, 
1560. 
17) Shim, J.; Welsh, W.; Cartier, E., J. Med. Chem. 2002, 45, 1447. 
51 
 
18) Zhang, Y.; Gilliam, A.; Maitra, R., J. Med. Chem. 2010, 53, 7048. 
19) Elsebai, M; Rempel, V.; Schnakenburg, G., ACS Med. Chem. Lett. 
2011, 2 (11), 886. 
20) Ooms, F.; Wouters, J.; Oscari, O., J. Med. Chem. 2002, 45, 1748. 
21) Jagerovic, N.; Hernandez-Folgado, L.; Alkorta, I., J. Med. Chem. 
2004, 47, 2939. 
22) Cararas, S., PhD Dissertation 2007. 
23) Bottini, A.; Dev, V.; Klink, J., Organic Synthesis, Coll. 1963, 5, 121. 
24) De Smaele, D.; Dejaegher, Y.; De Kimpe, N., Tetrahedron Lett. 2001, 
42, 2373.  
25) Hillier, M.; Chen, C., J. Org. Chem. 2006, 71, 7885. 
26) Dejaegher, Y; Mangelinckx, S; De Kimpe, N, Synlett. 2002, 28, 113. 
27) Sasse, A; Stark, H; Ligneau, X., Bio & Med. Chem. 2000, 8, 1139. 
28) Kretchmer, R., J. Org. Chem. 1972, 72, 2747. 
29) Kelly, T.; Moiseyeva, R., J. Org. Chem. 1998, 63, 3147. 
30) Leblanc, Y.; Fitzsimmons, B.; Adams, J., J. Org. Chem. 1986, 51, 
789. 
31) White, R.; Keaney, G.; Slown, C.; Wood, J., Org. Lett. 2004, 6, 1123. 
32) Ferrie, L.; Reymond, S.; Capdevielle, P.; Cossy, J., Org. Lett. 2006, 8, 
3441. 
33) Nicolaou, K.; Winssiger, N.; Pastor, J., J. Am. Chem. Soc. 
1997,119,449. 
34) Khan, A.; Mondal, E., Synlett, 2003, 5, 694. 
35) Wolinsky, J.; Ray, W.; Colson, Y.; Grinstaff, M., Macromolecules, 
2007, 40, 7065 
 
52 
 
Vita 
Kimari Slaughter was born in Baton Rouge, Louisiana.  She received her 
Bachelor’s degree in Chemistry from Xavier University of Louisiana in 2002.  She 
joined the University of New Orleans chemistry graduate program to pursue a 
Masters in Organic Chemistry and became a member of Mark L. Trudell’s research 
group in 2005.  She is currently studying for the MCAT in preparation for medical 
school. 
 
